Martin Gleave, MD, FRCSC, FACS

Vancouver Prostate Centre

Vancouver, British Columbia, Canada

Dr. Gleave is a Distinguished Professor and Chairman of the Department of Urologic Sciences at the University of British Columbia in Vancouver, as well as a British Columbia Leadership Chair. He is Co-Founder and Director of the Vancouver Prostate Centre, now a UBC and National Centre of Excellence, publishing more than 560 papers with more than 47,000 citations, an H-Index of 111, and attracting more than $120M in research funding. Dr. Gleave is a clinician-scientist and urologic surgeon whose clinical practice focuses on urologic oncology in a multi-disciplinary environment spanning localized and advanced cancers. His research characterizes molecular mechanisms mediating treatment resistance in cancer, focusing on adaptive survival responses that drive acquired treatment resistance, and designing combination co-targeting strategies to create conditional lethality and improve cancer control. He patented several anti-cancer drugs and founded OncoGenex Pharmaceuticals to develop OGX-011 and OGX-427, inhibitors of cytoprotective chaperones clusterin and Hsp27 which progressed to Phase III and Phase II trials world-wide. OncoGenex was awarded Canadian Biotech Company of the Year in 2010. Dr. Gleave also co-founded TRiADD and Sustained Therapeutics.

Dr Gleave is the recipient of numerous awards, including the Dr. Chew Wei Memorial Prize in Cancer Research, the Huggins Medal from the SUO, the Richard Williams Award from the AUA, the Barringer Medal from the American Association of GU Surgeons, the Eugene Fuller Award from the American Urological Association in 2013, the Aubrey Tingle Prize from the Michael Smith Foundation for Health Research, and the NCIC William Rawls Award for contributions to cancer control in Canada. He was appointed a Distinguished University Scholar at UBC in 2003 and awarded a BC Leadership Chair in 2005. Dr Gleave was awarded the 2006 BC Biotech Award for Innovation and Achievement, and the 2007 BC Innovation Council Frontiers in Research Award.
In 2017, Dr. Gleave was appointed to the Order of Canada for his leadership role in developing new treatments for prostate cancer and for his research on mechanisms mediating treatment resistance in cancer.

Disclosures: